+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Cervical Cancer Market by Type; by Products; by End-Users; and by Region, Market Outlook 2027

  • ID: 5129605
  • Report
  • July 2020
  • Region: Global
  • 102 Pages
  • Rockville Research
The Global Cervical Cancer Market is Estimated to be Valued at US$ 10.3 Billion in the Year 2027, Growing at a CAGR of 5.2%

FEATURED COMPANIES

  • Abbott Laboratories
  • Becton, Dickinson and Co.
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche
  • GlaxoSmithKline Plc
  • Hologic, Inc.
  • MORE

Industry Insights

According to this new report, the global cervical cancer market is estimated to be valued at US$ 10.3 billion in the year 2027, growing at a CAGR of 5.2% in the period 2020 to 2027. Growth of the market is driven by the prevalence of cervical cancer cases, rising incidences of HIV in women, increasing healthcare expenditure, favorable government initiatives and the advent of targeted therapies.

Cervical cancer is one of the most commonly diagnosed cancers among women. It is also the leading cause of cancer death. It is caused due to uncontrolled growth of tissues in the cervix which eventually leads to massive cancerous growth. Cervical cancers are broadly classified into three categories - Squamous Cell Carcinoma, Adenocarcinoma and Adenosquamous Carcinomas.

T-cell immunotherapy provides immense growth opportunities for cervical cancer treatment. It is one of the few biologics that has been approved for cervical cancer treatment and has a broader therapeutic potential for the disease. There are several T-cell therapy drugs under the clinical trial pipeline of various companies that are expected to gain approval in the near-term.

Report Scope

This report “Global Cervical Cancer Market [By Type – Squamous Cell Carcinoma, Adenocarcinoma & Adenosquamous Carcinomas; By Products – Vaccine & Drugs; By End-Users – Palliative Care Clinics, Hospitals & Diagnostic Canters; By Region- North America (The US), Europe (The UK & Germany) & Asia Pacific (China & India)] Market Outlook 2027” provides detailed analysis of the global cervical cancer market from qualitative and quantitative outlooks during the forecast period across various market segments and regional markets. It also provides coverage on market dynamics with potential impact on the market during the forecast period and an in-depth analysis of the leading companies operating in the market.

Parameter Description

  • Base year: 2015
  • Forecast period: 2020 – 2027
  • Market sizing: Revenue in US$ Billions & CAGR for the period 2015 to 2027
  • Country coverage: The US, Germany, The UK, India & China
  • Vendor scope: Bristol-Myers Squibb Co., F. Hoffmann-La Roche, GlaxoSmithKline Plc, Merck & Co., Inc., Novartis AG, Abbott Laboratories, Becton, Dickinson and Co., Hologic, Inc., QIAGEN
  • Report coverage: Revenue forecast, market share analysis, company analysis, competitive landscape, market growth drivers, market restraints, market trends and company profiles

Segments Covered

The report provides revenue forecasts for global, regional and country levels. It also provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. For the purpose of research, the publisher has segmented global cervical cancer market reports on the basis of geography, products, types and end-users.

Type Outlook, Revenue (2018 - 2027E, US$ Billions)

  • Squamous Cell Carcinoma
  • Adenocarcinoma
  • Adenosquamous Carcinomas

Product Outlook, Revenue (2018 - 2027E, US$ Billions)

  • Vaccine
  • Drugs

Regional Outlook, Revenue (2015 - 2027E, US$ Billions)

  • North America
  • Europe
  • Asia Pacific

Country Outlook, Revenue (2015 - 2027E, US$ Billions)

  • The US
  • Germany
  • The UK
  • India
  • China

Vendors Outlook, Revenue (2015 - 2019, US$ Billions)

  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche
  • GlaxoSmithKline Plc
  • Merck & Co., Inc.
  • Novartis AG
  • Abbott Laboratories
  • Becton, Dickinson and Co.
  • Hologic, Inc.
  • QIAGEN

Target Audience

  • Device Manufacturers
  • Drug Manufacturers
  • End Users
  • Research Professionals
  • Healthcare Consultancies
  • Regulatory Bodies

Key questions answered in the report

  • The historical market size of the cervical cancer market from 2015 to 2019 in US$ Billions.
  • Projected market growth in the forecasted period 2020 to 2027 with estimated revenue for each year in US$ Billions.
  • Regional and country analysis of the cervical cancer market is provided for the period 2015 to 2027.
  • Market drivers, restraints and industry trends that have an impact on revenue.
  • Profiling of major companies with a detailed analysis of their cervical cancer vaccines and drugs.

Customization

The publisher provides customization of the study in order to provide specific information as sought by the client.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Becton, Dickinson and Co.
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche
  • GlaxoSmithKline Plc
  • Hologic, Inc.
  • MORE

1. Executive Summary

2. Research Methodology

3. Cervical Cancer
3.1 Overview
3.2 Types
3.2.1 Squamous Cell Carcinoma
3.2.2 Adenocarcinoma
3.2.3 Adenosquamous Carcinomas
3.3 Diagnosis & Treatment
3.3.1 Diagnosis
3.3.2 Treatment

4. Market Analysis
4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Type
4.2.2 Market Share by Products
4.2.3 Market Share by Cause of Disease
4.2.4 Market Share by End-Users
4.2.5 Market Share by Region

5. Market Segmentation
5.1 By Type
5.1.1 Squamous Cell Carcinoma (SCC)
5.1.1.1 Market Sizing (Actual & Forecasted)
5.1.2 Adenocarcinoma
5.1.2.1 Market Sizing (Actual & Forecasted)
5.1.3 Adenosquamous Carcinomas
5.1.3.1 Market Sizing (Actual & Forecasted)
5.2 By Product
5.2.1 Vaccine
5.2.1.1 Market Sizing (Actual & Forecasted)
5.2.2 Drugs
5.2.2.1 Market Sizing (Actual & Forecasted)
5.3 By End-User
5.3.1 Palliative Care Clinics
5.3.1.1 Market Sizing (Actual & Forecasted)
5.3.2 Hospitals
5.3.2.1 Market Sizing (Actual & Forecasted)
5.3.3 Diagnostic Centers
5.3.3.1 Market Sizing (Actual & Forecasted)

6. Regional Analysis
6.1 North America
6.1.1 Market Sizing (Actual & Forecasted)
6.1.2 Market Share by Screening Test
6.1.3 The US
6.1.3.1 Market Sizing (Actual & Forecasted)
6.1.3.2 Market Share by Type
6.2 Europe
6.2.1 Market Sizing (Actual & Forecasted)
6.2.2 The UK
6.2.2.1 Market Sizing (Actual & Forecasted)
6.2.3 Germany
6.2.3.1 Market Sizing (Actual & Forecasted)
6.3 Asia Pacific
6.3.1 Market Sizing (Actual & Forecasted)
6.3.2 China
6.3.2.1 Market Sizing (Actual & Forecasted)
6.3.3 India
6.3.3.1 Market Sizing (Actual & Forecasted)

7. Market Dynamics
7.1 Industry Trends & Developments
7.1.1 T-cell Immunotherapy for Cervical Cancer
7.1.2 Higher Adoption of HPV Home Testing
7.1.3 Robotic Surgery for Cervical Cancer
7.2 Growth Drivers
7.2.1 Prevalence of Cervical Cancer
7.2.2 Rising Incidences of HIV in Women
7.2.3 Increasing Healthcare Expenditure
7.2.4 Advent of Targeted Therapies
7.2.5 Favorable Government Initiatives
7.3 Challenges
7.3.1 Stringent Regulatory Compliance
7.3.2 High Cost of Treatment
7.3.3 Lack of Awareness

8. Competitive Landscape
8.1 Drug Analysis
8.2 Financial Analysis

9. Company Profiles
9.1 Bristol-Myers Squibb Co.
9.2 F. Hoffmann-La Roche
9.3 GlaxoSmithKline Plc
9.4 Merck & Co., Inc.
9.5 Novartis AG
9.6 Abbott Laboratories
9.7 Becton, Dickinson and Co.
9.8 Hologic, Inc.
9.9 QIAGEN

List of Figures and Tables
Figure 1: Research Methodology
Figure 2: Anatomy of the Female Reproductive System
Figure 3: Global Cervical Cancer Treatment Market Size by Value, 2015-27E (US$ Billions)
Figure 4: Global Cervical Cancer Treatment Market Share by Type (2019)
Figure 5: Global Cervical Cancer Treatment Market Share by Treatment Products (2019)
Figure 6: Global Cervical Cancer Treatment Market Share by Cause of Disease (2019)
Figure 7: Global Cervical Cancer Treatment Market Share by End-Users (2019)
Figure 8: Global Cervical Cancer Treatment Market Share by Region (2019)
Figure 9: Global Cervical Cancer by Type - Squamous Cell Carcinoma (SCC) Market Size by Value, 2018-27E (US$ Billions)
Figure 10: Global Cervical Cancer by Type - Adenocarcinoma Market Size by Value, 2018-27E (US$ Billions)
Figure 11: Global Cervical Cancer by Type - Adenosquamous Carcinomas Market Size by Value, 2018-27E (US$ Billions)
Figure 12: Global Cervical Cancer by Products - Vaccine Market Size by Value, 2018-27E (US$ Billions)
Figure 13: Global Cervical Cancer by Products - Drugs Market Size by Value, 2018-27E (US$ Billions)
Figure 14: Global Cervical Cancer by End-Users - Palliative Care Clinics Market Size by Value, 2018-27E (US$ Billions)
Figure 15: Global Cervical Cancer by End-Users - Hospitals Market Size by Value, 2018-27E (US$ Billions)
Figure 16: Global Cervical Cancer by End-Users - Diagnostic Centers Market Size by Value, 2018-27E (US$ Billions)
Figure 17: North America Cervical Cancer Treatment Market Size by Value, 2015-27E (US$ Billions)
Figure 18: North America Cervical Cancer Treatment Market Share by Test Type (2019)
Figure 19: The US Cervical Cancer Treatment Market Size by Value, 2015-27E (US$ Billions)
Figure 20: The US Cervical Cancer Treatment Market Share by Type (2020E)
Figure 21: Europe Cervical Cancer Treatment Market Size by Value, 2015-27E (US$ Billions)
Figure 22: The UK Cervical Cancer Incidences, 2015-20E (Millions)
Figure 23: Germany Cervical Cancer Incidences, 2015-20E (Millions)
Figure 24: Asia Pacific Cervical Cancer Treatment Market Size by Value, 2015-27E (US$ Billions)
Figure 25: China Cervical Cancer Incidences, 2015-20E (Millions)
Figure 26: India Cervical Cancer Incidences, 2015-20E (Millions)
Figure 27: Global Cervical Cancer Incidences, 2013-20E (Millions)
Figure 28: Incidence Rates of Cervical Cancer Worldwide (per 100,000 women) by Region (2019)
Figure 29: Global Prevalence of HIV, 2000-19 (Millions)
Figure 30: Correlation between HIV Incidence & HPV
Figure 31: Global Healthcare Expenditure, 2013-20 (US$ Trillions)
Table 1: Global Cervical Cancer Therapeutics Analysis by Companies
Table 2: Global Cervical Cancer Therapeutics Clinical Analysis
Table 3: Drugs Approved for Treatment & Prevention of Cervical Cancer
Table 4: Cervical Cancer Treatment Drugs - Generic & Trade Names
Table 5: Global Cervical Cancer Market Players Revenue Comparison, FY2018-22E (US$ Billions)
Table 6: Global Cervical Cancer Market Players Financial Analysis (FY2020)
Figure 32: Bristol-Myers Squibb Co. Revenue by Business Segment (FY2019)
Figure 33: Bristol-Myers Squibb Co. Net Sales, FY2015 - FY2019 (US$ Billions)
Figure 34: F. Hoffmann-La Roche Revenue by Business Segment (FY2019)
Figure 35: F. Hoffmann-La Roche Net Sales, FY2015 - FY2019 (US$ Billions)
Figure 36: GlaxoSmithKline Plc Revenue by Business Segment (FY2019)
Figure 37: GlaxoSmithKline Plc Net Sales, FY2015 - FY2019 (US$ Billions)
Figure 38: Merck & Co., Inc. Revenue by Business Segment (FY2019)
Figure 39: Merck & Co., Inc. Net Sales, FY2015 - FY2019 (US$ Billions)
Figure 40: Novartis AG Revenue by Business Segment (FY2019)
Figure 41: Novartis AG Net Sales, FY2015 - FY2019 (US$ Billions)
Figure 42: Abbott Laboratories Revenue by Business Segment (FY2019)
Figure 43: Abbott Laboratories Net Sales, FY2015 - FY2019 (US$ Billions)
Figure 44: Becton, Dickinson and Co. Revenue by Business Segment (FY2019)
Figure 45: Becton, Dickinson and Co. Net Sales, FY2015 - FY2019 (US$ Billions)
Figure 46: Hologic, Inc. Revenue by Business Segment (FY2019)
Figure 47: Hologic, Inc. Net Sales, FY2015 - FY2019 (US$ Billions)
Figure 48: QIAGEN Revenue by Business Segment (FY2019)
Figure 49: QIAGEN Net Sales, FY2015 - FY2019 (US$ Billions)

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Becton, Dickinson and Co.
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche
  • GlaxoSmithKline Plc
  • Hologic, Inc.
  • MORE

Cervical cancer is the type of cancer that develops in the tissues of the cervix (the organ connecting the uterus and vagina). It is most commonly caused by the human papillomavirus (HPV). Cervical cancers are broadly classified into three categories - Squamous Cell Carcinoma, Adenocarcinoma, and Adenosquamous Carcinomas. Squamous Cell Carcinoma which begins in the transformation zone is the most common type of cervical cancer accounting for 90% of total cervical cancer incidences. Diagnosis of cervical cancer includes screening tests such as the Pap test and HPV DNA test. Pap test is the most common screening test for the detection of cervical cancer or precancerous cells.

Cervical cancer is the leading cause of cancer-related death in women worldwide. It is the eighth most common form of cancer. The global cervical cancer market is driven by rising incidences of cervical cancer and prevalence of HIV cases in women worldwide. The disease ranks as the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death in women. Growth of the market is further fuelled by increasing healthcare expenditure, the advent of targeted therapies and favorable government initiatives toward cervical cancer prevention and early diagnosis of the disease. However, the market faces several challenges due to stringent regulatory compliance, high cost of treatment and lack of awareness.

The report “Global Cervical Cancer Market [By Type - Squamous Cell Carcinoma, Adenocarcinoma & Adenosquamous Carcinomas; By Products - Vaccine & Drugs; By End-Users - Palliative Care Clinics, Hospitals & Diagnostic Centers; By Region- North America (The US), Europe (The UK & Germany) & Asia Pacific (China & India)] Market Outlook 2027” provides an in-depth analysis of the current scenario, detailed market outlook of the global cervical cancer market. The market is segmented by disease type, products and end-users. Future forecasts of the cervical cancer market overall and across various regional markets have been provided in the report until 2027. Furthermore, major industry players have been prudently analyzed in the competitive landscape section of the report in order to provide key comparative insights.

Major industry players operating in the global cervical cancer market include Bristol-Myers Squibb Co., F. Hoffmann-La Roche, GlaxoSmithKline Plc, Merck & Co., Inc., Novartis AG, Abbott Laboratories, Becton, Dickinson and Co., Hologic, Inc., QIAGEN, among others. These players are profiled herein based on attributes such as business overview, product segments, and financial analysis. It also compiles the performance comparison of the aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in the global cervical cancer market.

Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • Becton, Dickinson and Co.
  • Bristol-Myers Squibb Co.
  • F. Hoffmann-La Roche
  • GlaxoSmithKline Plc
  • Hologic, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • QIAGEN
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll